Truist Financial’s Lexicon Pharmaceuticals LXRX Stock Holding History

Truist Financial’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.8K	Hold	14,000	–	–	﹤0.01%	2773
2025 Q4	$16.1K	Hold	14,000	–	–	﹤0.01%	2751
2025 Q3	$18.9K	Hold	14,000	–	–	﹤0.01%	2702
2025 Q2	$13.2K	Hold	14,000	–	–	﹤0.01%	2583
2025 Q1	$6.45K	Hold	14,000	–	–	﹤0.01%	2539
2024 Q4	$10.3K	Buy	14,000 +600	+4%	+$723	﹤0.01%	2504
2024 Q3	$21K	Hold	13,400	–	–	﹤0.01%	2470
2024 Q2	$22.5K	Buy	13,400 +400	+3%	+$718	﹤0.01%	2620
2024 Q1	$31.2K	Buy	13,000 +500	+4%	+$1.07K	﹤0.01%	2593
2023 Q4	$19.1K	Buy	12,500 +500	+4%	+$595	﹤0.01%	2616
2023 Q3	$13.1K	Buy	+12,000	New	+$21.1K	﹤0.01%	2569

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Truist Financial's LXRX Position: Q1 2026 in Review

Truist Financial held its Lexicon Pharmaceuticals (LXRX) position steady in Q1 2026 at 14,000 shares worth $21.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2773.

Truist Financial first reported a position in LXRX in Q3 2023 and has held it in 11 quarters since. The position peaked at $31.2K in Q1 2024. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

Truist Financial held 14,000 shares of Lexicon Pharmaceuticals worth $21.8K as of Q1 2026.
Truist Financial left its Lexicon Pharmaceuticals share count unchanged in Q1 2026.
Lexicon Pharmaceuticals made up ﹤0.01% of Truist Financial's portfolio in Q1 2026, its #2773 holding.
Truist Financial first reported a position in Lexicon Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Truist Financial's Lexicon Pharmaceuticals position peaked at $31.2K in Q1 2024.
136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Truist Financial's 13F filing for Q1 2026, filed 27 Apr 2026.